What are your top takeaways in Gyn Cancers from ASCO 2024?
3 Answers
Mednet MemberInvited Expert
Radiation Oncology · Harold C Simmons Comprehensive Cancer Center/UT Southwestern
Answered on
ASCO 2024 was a quiet year for the gynecological cancer community without too many fireworks. For the radiation oncologists, there were very few positive studies. I will highlight a few important ones
1. Oral abstract #5504 was on “Adjuvant chemotherapy following concurrent chemoradiation (CRT) in p...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on
NRG oncology/RTOG 0724/GOG-0724 - NRG study for adjuvant chemotherapy after concurrent chemo RT for high-risk post operative cervical cancer showed no difference in recurrence pattern and DFS with the addition of chemotherapy. As expected, grade 3-4 acute complications were higher with the addition ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Gynecologic Oncology · Center of Hope
Answered on
Numerous important gynecologic oncology studies were presented at ASCO 2024. The following three are clinically important and/or practice-changing.
- CARACO Trial (NCT01218490) - Omission of Lymphadenectomy in Advanced Epithelial Ovarian Cancer
CARACO is a large (n=450) multicenter randomized phase II...
Join for free or sign in to see the full answer